CTOs on the Move

Delaware Health Information Network

www.dhin.org

 
In 2007 the Delaware Health Information Network (DHIN) became the first live, statewide health information network in the nation. DHIN currently serves: - 100% of Delaware’s acute care hospitals - 100% of Delaware’s long term care and skilled nursing facilities - Approaching 100% of medical providers who have enrolled and are participating in DHIN More than 14,000,000 clinical results and reports are posted on DHIN each year – and the total patient records in the system now exceed 2,100,000, featuring patient records from all 50 states. In the six years that DHIN has been active, the system has proven its reliability and worth to hospitals, ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.dhin.org
  • 107 Wolf Creek Blvd Suite 2
    Dover, DE USA 19901
  • Phone: 302.678.0220

Executives

Name Title Contact Details

Similar Companies

Hendricks Regional Health

Hendricks Regional Health is a non-profit, multi-specialty healthcare organization caring for communities in the Western and Central suburban area of Indianapolis since 1962, with a full-service hospital in Danville and medical buildings in Avon, Bainbridge, Brownsburg, Plainfield and Lizton. In December 2017, we will be opening our second hospital to serve the growing needs of the Brownsburg area.

F-D-C Reports

F-D-C Reports, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surveillance Data

Surveillance Data is a Morrisville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART LinkerSM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.

Menlo Therapeutics

We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus associated with various conditions.